Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced the appointment of Kate Madigan, MD,...
Hemab Therapeutics, a biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombosis disorders, unveiled its lead candidate, HMB-001, a novel bispecific antibody...
